PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
41.81%
EBIT growth of 41.81% while CRON.TO is zero. Bruce Berkowitz would see if small gains can be scaled further.
41.81%
Operating income growth of 41.81% while CRON.TO is zero. Bruce Berkowitz would see if this modest edge can become significant.
45.90%
Net income growth of 45.90% while CRON.TO is zero. Bruce Berkowitz would see if small gains can accelerate into a larger gap.
47.62%
EPS growth of 47.62% while CRON.TO is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
47.62%
Diluted EPS growth of 47.62% while CRON.TO is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4156.92%
Negative OCF growth while CRON.TO is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-4156.92%
Negative FCF growth while CRON.TO is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-103.85%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-103.85%
Negative 5Y OCF/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-103.85%
Negative 3Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
83.46%
10Y net income/share CAGR of 83.46% while CRON.TO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
83.46%
Net income/share CAGR of 83.46% while CRON.TO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
83.46%
3Y net income/share CAGR of 83.46% while CRON.TO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
-57.10%
Negative equity/share CAGR over 10 years while CRON.TO stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-57.10%
Negative 5Y equity/share growth while CRON.TO is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-57.10%
Negative 3Y equity/share growth while CRON.TO is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
56.34%
AR growth of 56.34% while CRON.TO is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
No Data
No Data available this quarter, please select a different quarter.
-3.01%
Negative asset growth while CRON.TO invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-2.09%
We have a declining book value while CRON.TO shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-41.81%
We cut SG&A while CRON.TO invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.